Black Friday Sale! Save huge on InvestingProGet up to 60% off

Agilon Health Gains on Earnings Beat, Despite Revenue Miss

Published 2024-05-07, 04:18 p/m
© Reuters.
AGL
-

AUSTIN, Texas - Agilon Health Inc. (NYSE: AGL) shares climbed 2.4% following the announcement of its first-quarter earnings, which exceeded analysts' expectations.

The company reported an adjusted EPS of $0.01, surpassing the consensus estimate that predicted a loss of $0.01. However, revenue for the quarter was slightly below expectations at $1.6 billion, compared to the anticipated $1.61 billion.

In the first quarter of 2024, Agilon Health saw a significant 52% increase in revenue compared to the same period last year, rising from $1.05 billion to $1.6 billion. This growth was accompanied by a 43% increase in Medicare Advantage membership, which reached 523,000 members. The total number of members on the Agilon platform grew to 654,000.

Despite the revenue shortfall, the market responded positively to the earnings beat, with the company's stock rising. Agilon Health's CEO, Steve Sell, attributed the strong quarter to the company's execution of its performance action plan, which is focused on driving profitability and enhancing operating efficiency.

"Our first quarter results were in-line with our guidance," said Sell. "We continue to make tangible progress executing our performance action plan. As payors adjust to the current funding environment for Medicare Advantage, we remain well positioned as our value proposition to primary care doctors and payors is increasingly important and well-recognized."

For the second quarter of 2024, Agilon Health provided guidance for revenue between $1.55 billion and $1.57 billion, which is below the consensus estimate of $1.6 billion. For the full year, the company expects revenue to be between $6.125 billion and $6.175 billion, also lower than the consensus estimate of $6.396 billion.

The company's continued progress on its performance action plan includes refining payer relationships, expanding support for new primary care physicians, and improving data visibility and analytics. These actions are anticipated to support growth in adjusted EBITDA in 2024 and beyond.

Agilon Health maintains its full-year 2024 guidance for Medical Margin and Adjusted EBITDA, signaling confidence in its strategic direction and operational improvements. The company's capital position remains strong, with a balance sheet showing $426 million in cash, cash equivalents, and marketable securities, and total debt of $37 million as of March 31, 2024.

Investors are encouraged by the company's earnings beat and the strategic initiatives underway, as reflected in the positive stock movement. Agilon Health continues to focus on empowering physicians to transform healthcare in communities, with a growing network that now includes over 3,000 primary care physicians.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.